2017_SBRT_Course Book
Dose in relation to volume: OARs
Acceptable variation in Gy l i i i
Unacceptable variation in Gy ≥8*5.81=46.68 t le i ti i . .
Unacceptable variation EqD2 in Gy c e t le ri ti i y
αβ
D max in Gy
EqD2 in Gy
OAR
i n G y y i
3 3 3 3 2 3 3 3 3
8*5.5= 44 8*5.5= 44 8*5.5= 44 8*5 = 40 8*4= 32 8*4.75=38
74.8 . 74.8 74.8
<8*5.81=46.68 . .
≥81.9 .
Trachea/ MainBronchus
Heart §
t *
<8*6=48 <8*6=48
≥8*6=48 ≥8*6=48
≥86.4 ≥86.4
GreatVessels § t e sels * Esophagus SpinalCord & BrachialPlexus &
64 48
<8*5.44=43.52 . .
≥8*5.44=43.52 . .
≥73.6 .
>8*4=32
≥48
58.9 .
<8*5.17=41.36 . .
≥8*5.17=41.36 . .
≥ 67.7 6 .
External-PTV &
8*7.5= 60
126
<8*7.785=62.28 . .
≥134.2 .
≥8*7.785=62.28 . .
Lungs-CTV § ChestWall § - l §
*
V20Gy<6%
V20<10%
V20Gy≥10%
8*8.25=66
148.5
≥8*9=72
≥172.8
& for <0.5 cc § no restrictions are provided but recording of DVH data for toxicity evaluation is required EORTC 22113-0813-LungTech RTQA Guidelines t t i it l ti is r ir Catharina Cancer Centre guidelines
Adebahr S et al. BJR 2015, EORTC Lungtech trial
* Following Mangona, IJROBP 91(1) p124-132 2015, William Beaumont Hospital
Made with FlippingBook Annual report